SCHEMBL6062009

SCHEMBL6062009

O=C(NC(CS(=O)(=O)Cc1cccnc1)C(=O)N(CCCc1ccccc1)C(=O)c1nc2ccccc2o1)c1cnccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LONP1 P36776 13/20 0.42
PSMB5 P28074 11/20 0.42
PSMB8 P28062 10/20 0.42
PSMB9 P28065 10/20 0.42
PSMB6 P28072 10/20 0.42
PSMB10 P40306 10/20 0.42
PSMB11 A5LHX3 9/20 0.42
PSMA7 O14818 9/20 0.42
PSMB1 P20618 9/20 0.42
PSMA1 P25786 9/20 0.42
PSMA2 P25787 9/20 0.42
PSMA3 P25788 9/20 0.42
PSMA4 P25789 9/20 0.42
PSMA5 P28066 9/20 0.42
PSMB4 P28070 9/20 0.42
PSMB3 P49720 9/20 0.42
PSMB2 P49721 9/20 0.42
PSMA6 P60900 9/20 0.42
PSMA8 Q8TAA3 9/20 0.42
PSMB7 Q99436 9/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6465501 0.96 LONP1 (0.43) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL6466564 0.88 DAGLA (0.41) DAGLAFAAHCES1
SCHEMBL6062013 0.82 LONP1 (0.46) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL7043352 0.82 DAGLA (0.39) DAGLAFAAHCES1CTSL
SCHEMBL7049518 0.80 DAGLA (0.46) DAGLAFAAHCES1CTSGCMA1
SCHEMBL6465503 0.78 LONP1 (0.48) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL6466062 0.77 DAGLA (0.37) DAGLAFAAHCES1CTSL
SCHEMBL7048614 0.77 DAGLA (0.41) DAGLAFAAHCES1CTSL
SCHEMBL7047997 0.77 LONP1 (0.45) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL6468438 0.76 FAAH (0.40) DAGLAFAAHCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1694357-A1 USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC AXYS PHARMACEUTICALS, INC. (US) 2006-08-30 EP disclosed
WO-2005058348-A1 USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC AXYS PHARMACEUTICALS, INC. (US) 2005-06-30 WO disclosed